Novavax, Inc. : Novavax Announces Management Promotion
(Thomson Reuters ONE) -
GAITHERSBURG, Md., April 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced that Iksung Cho has been named Vice President,
Biostatistics.
Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics
with responsibility for coordinating statistical and statistical programming
activities for vaccine candidates in various stages of clinical development.
Prior to joining Novavax he was Senior Statistician at PATH, an international
nonprofit organization that aims to accelerate innovation across vaccines,
drugs, diagnostics, devices and system and service innovations.
Mr. Cho's experience includes positions of increasing responsibility in
biostatistics and data management at Aviron, Merck and MedImmune, where he was
Vice President of Global Biostatistics. He earned Master's degrees in both
statistics and applied mathematics from Virginia Polytechnic and State
University and completed graduate studies in mathematics.
"Iksung has rapidly become a critical part of our team," said Gregory M. Glenn,
M.D., President, Research and Development. "We expect to leverage his deep
experience in biostatistics to evaluate important data readouts from the pivotal
Phase 3 Resolve trial of our RSV F Vaccine in older adults and the Phase 2
rollover trial in older adults later this year."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases. Its
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir(at)novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull(at)russopartnersllc.com
todd.davenport(at)russopartnersllc.com
212-845-4271
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
[HUG#1999941]
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2016 - 22:05 Uhr
Sprache: Deutsch
News-ID 461785
Anzahl Zeichen: 2990
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax, Inc. : Novavax Announces Management Promotion"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
